122 related articles for article (PubMed ID: 23148625)
21. Cytoplasmic accumulation of activated leukocyte cell adhesion molecule is a predictor of disease progression and reduced survival in oral cancer patients.
Sawhney M; Matta A; Macha MA; Kaur J; DattaGupta S; Shukla NK; Ralhan R
Int J Cancer; 2009 May; 124(9):2098-105. PubMed ID: 19142865
[TBL] [Abstract][Full Text] [Related]
22. ALCAM is associated with chemoresistance and tumor cell adhesion in pancreatic cancer.
Hong X; Michalski CW; Kong B; Zhang W; Raggi MC; Sauliunaite D; De Oliveira T; Friess H; Kleeff J
J Surg Oncol; 2010 Jun; 101(7):564-9. PubMed ID: 20461761
[TBL] [Abstract][Full Text] [Related]
23. MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma.
Verma A; Shukla NK; Deo SV; Gupta SD; Ralhan R
Oncology; 2005; 68(4-6):462-70. PubMed ID: 16024937
[TBL] [Abstract][Full Text] [Related]
24. Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer.
Ihnen M; Müller V; Wirtz RM; Schröder C; Krenkel S; Witzel I; Lisboa BW; Jänicke F; Milde-Langosch K
Breast Cancer Res Treat; 2008 Dec; 112(3):419-27. PubMed ID: 18172759
[TBL] [Abstract][Full Text] [Related]
25. ALCAM (CD166) is a surface marker for early murine cardiomyocytes.
Hirata H; Murakami Y; Miyamoto Y; Tosaka M; Inoue K; Nagahashi A; Jakt LM; Asahara T; Iwata H; Sawa Y; Kawamata S
Cells Tissues Organs; 2006; 184(3-4):172-80. PubMed ID: 17409743
[TBL] [Abstract][Full Text] [Related]
26. The role of activated leukocyte cell adhesion molecule (ALCAM) in cancer progression, invasion, metastasis and recurrence: A novel cancer stem cell marker and tumor-specific prognostic marker.
Darvishi B; Boroumandieh S; Majidzadeh-A K; Salehi M; Jafari F; Farahmand L
Exp Mol Pathol; 2020 Aug; 115():104443. PubMed ID: 32380056
[TBL] [Abstract][Full Text] [Related]
27. Human blastocysts and endometrial epithelial cells express activated leukocyte cell adhesion molecule (ALCAM/CD166).
Fujiwara H; Tatsumi K; Kosaka K; Sato Y; Higuchi T; Yoshioka S; Maeda M; Ueda M; Fujii S
J Clin Endocrinol Metab; 2003 Jul; 88(7):3437-43. PubMed ID: 12843199
[TBL] [Abstract][Full Text] [Related]
28. Serum activated leukocyte cell adhesion molecule and intercellular adhesion molecule-1 in patients with gastric cancer: Can they be used as biomarkers?
Erturk K; Tastekin D; Bilgin E; Serilmez M; Bozbey HU; Sakar B
Biomed Pharmacother; 2016 Feb; 77():86-91. PubMed ID: 26796270
[TBL] [Abstract][Full Text] [Related]
29. EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis.
Ralhan R; Cao J; Lim T; Macmillan C; Freeman JL; Walfish PG
BMC Cancer; 2010 Jun; 10():331. PubMed ID: 20579375
[TBL] [Abstract][Full Text] [Related]
30. ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions.
Kristiansen G; Pilarsky C; Wissmann C; Stephan C; Weissbach L; Loy V; Loening S; Dietel M; Rosenthal A
Prostate; 2003 Jan; 54(1):34-43. PubMed ID: 12481253
[TBL] [Abstract][Full Text] [Related]
31. Activated leukocyte cell-adhesion molecule (ALCAM) promotes malignant phenotypes of malignant mesothelioma.
Ishiguro F; Murakami H; Mizuno T; Fujii M; Kondo Y; Usami N; Yokoi K; Osada H; Sekido Y
J Thorac Oncol; 2012 May; 7(5):890-9. PubMed ID: 22722789
[TBL] [Abstract][Full Text] [Related]
32. Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: a TMA-based immunohistochemical study on 2,197 breast cancer patients.
Burandt E; Bari Noubar T; Lebeau A; Minner S; Burdelski C; Jänicke F; Müller V; Terracciano L; Simon R; Sauter G; Wilczak W; Lebok P
Oncol Rep; 2014 Dec; 32(6):2628-34. PubMed ID: 25270339
[TBL] [Abstract][Full Text] [Related]
33. Different subcellular localization of ALCAM molecules in neuroblastoma: Association with relapse.
Corrias MV; Gambini C; Gregorio A; Croce M; Barisione G; Cossu C; Rossello A; Ferrini S; Fabbi M
Cell Oncol; 2010; 32(1-2):77-86. PubMed ID: 20208136
[TBL] [Abstract][Full Text] [Related]
34. ALCAM, Activated Leukocyte Cell Adhesion Molecule, in Clinical Gastric Cancer and Patient's Response to Chemotherapies.
Yang YM; Ruge F; Ji KE; Jia S; Jia Y; Sanders AJ; Ji J; Jiang WG
Anticancer Res; 2023 Apr; 43(4):1463-1475. PubMed ID: 36974802
[TBL] [Abstract][Full Text] [Related]
35. Internalization and recycling of ALCAM/CD166 detected by a fully human single-chain recombinant antibody.
Piazza T; Cha E; Bongarzone I; Canevari S; Bolognesi A; Polito L; Bargellesi A; Sassi F; Ferrini S; Fabbi M
J Cell Sci; 2005 Apr; 118(Pt 7):1515-25. PubMed ID: 15769845
[TBL] [Abstract][Full Text] [Related]
36. Activated Leukocyte Cell Adhesion Molecule (ALCAM) is associated with suppression of breast cancer cells invasion.
Jezierska A; Olszewski WP; Pietruszkiewicz J; Olszewski W; Matysiak W; Motyl T
Med Sci Monit; 2006 Jul; 12(7):BR245-56. PubMed ID: 16810131
[TBL] [Abstract][Full Text] [Related]
37. Expression of ALCAM in Clinical Colon Cancer and Relationship With Patients' Treatment Responses.
Fang Z; Zeng JJ; Yang Y; Ruge F; Lane J; Hargest R; Jiang WG
In Vivo; 2023; 37(3):1117-1128. PubMed ID: 37103072
[TBL] [Abstract][Full Text] [Related]
38. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R
Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273
[TBL] [Abstract][Full Text] [Related]
39. ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy.
Jezierska A; Matysiak W; Motyl T
Med Sci Monit; 2006 Aug; 12(8):BR263-73. PubMed ID: 16865058
[TBL] [Abstract][Full Text] [Related]
40. HLA-G is differentially expressed in thyroid tissues.
de Figueiredo Feitosa NL; Crispim JC; Zanetti BR; Magalhães PK; Soares CP; Soares EG; Neder L; Donadi EA; Maciel LM
Thyroid; 2014 Mar; 24(3):585-92. PubMed ID: 24089994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
